• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Axogen Inc. (Amendment)

    2/14/23 4:08:55 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AXGN alert in real time by email
    SC 13G/A 1 pt7213gaa.htm SCHEDULE 13G/A, AMENDMENT #1
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    (Name of Issuer)

    Axogen, Inc.

    (Title of Class of Securities)

    Common Stock, par value $0.01 per share

    (CUSIP Number)

    05463X106

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2022

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).


    CUSIP No. 05463X106
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,815,000
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,815,000
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,815,000
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.3%
     
    (12) Type of reporting person (see instructions) PN
     



    CUSIP No. 05463X106
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,815,000
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,815,000
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,815,000
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.3%
     
    (12) Type of reporting person (see instructions) CO
     



    CUSIP No. 05463X106
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              47,219
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       47,219
     
    (9) Aggregate amount beneficially owned by each reporting person
    47,219
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.1%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 05463X106
    (1) Names of reporting persons    Point72 Hong Kong Limited
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Hong Kong
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0
     
    (9) Aggregate amount beneficially owned by each reporting person
    0
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 05463X106
    (1) Names of reporting persons    Point72 Middle East FZE
    (2) Check the appropriate box if a member of a group
    (see instructions)
    (3) SEC use only
    (4) Citizenship or place of organization United Arab Emirates
    Number of shares beneficially owned by each reporting person with:
    (5) Sole voting power                  0
    (6) Shared voting power              2,364
    (7) Sole dispositive power           0
    (8) Shared dispositive power       2,364
    (9) Aggregate amount beneficially owned by each reporting person
    2,364
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
    (11) Percent of class represented by amount in Row (9) <0.1%
    (12) Type of reporting person (see instructions) OO



    CUSIP No. 05463X106
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,864,583
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,864,583
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,864,583
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.4%
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:

    Axogen, Inc.

    Item 1(b) Address of issuer's principal executive offices:

    13631 Progress Blvd., Suite 400, Alachua, FL 32615

    2(a) Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.01 per share
    (“Shares”), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors,
    Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by an investment fund
    managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist
    Systematic Strategies”) with respect to Shares held by an investment fund it manages; (iv)
    Point72 Hong Kong Limited (“Point72 Hong Kong”) with respect to Shares held by an
    investment fund it manages; (v) Point72 Middle East FZE (“Point72 Middle East”) with respect
    to Shares held by an investment fund it manages and (vi) Steven A. Cohen
    (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management, Point72
    Capital Advisors Inc., Cubist Systematic Strategies, Point72 Hong Kong, and Point72 Middle
    East.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
    Hong Kong, Point72 Middle East, and Mr. Cohen have entered into a Joint Filing Agreement, a
    copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have
    agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the
    Act.

    2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Point72 Asset Management, Point72 Capital
    Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; (ii) Cubist
    Systematic Strategies is 55 Hudson Yards, New York, NY 10001; (iii) Point72 Hong Kong is
    Suites 1102 – 1110, 11th Floor and 12th Floor, Chater House, 8 Connaught Road Central, Hong Kong;
    and (iv) Point72 Middle East is EO3, 04, Sheikh Rashid Tower, Dubai World Trade Centre,
    Dubai, United Arab Emirates.

    2(c) Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
    Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.
    Point72 Hong Kong is a Hong Kong limited liability company. Point72 Middle East is a limited
    liability free zone establishment.   Mr. Cohen is a United States citizen.

    2(d) Title of class of securities:

    Common Stock, par value $0.01 per share

    2(e) CUSIP Number:

    05463X106

    Item 3.

    Not applicable


    Item 4. Ownership

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for
    each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
    Such information is as of the close of business on December 31, 2022.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
    Hong Kong, Point72 Middle East, and Mr. Cohen own directly no Shares. Pursuant to an
    investment management agreement, Point72 Asset Management maintains investment and voting
    power with respect to the securities held by an investment fund it manages. Point72 Capital
    Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment
    management agreement, Cubist Systematic Strategies maintains investment and voting power
    with respect to the securities held by an investment fund it manages. Pursuant to an investment
    management agreement, Point72 Hong Kong maintains investment and voting power with
    respect to the securities held by an investment fund it manages. Pursuant to an investment
    management agreement, Point72 Middle East maintains investment and voting power with
    respect to the securities held by an investment fund it manages. Mr. Cohen controls each of
    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
    Hong Kong, and Point72 Middle East. The filing of this statement should not be construed as an
    admission that any of the foregoing persons or any reporting person is, for the purposes of
    Section 13 of the Act, the beneficial owner of the Shares reported herein.

    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    See Item 2(a).

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to
    above were not acquired and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired and are not held in
    connection with or as a participant in any transaction having that purpose or effect.


    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.


    Dated: February 14, 2023


    POINT72 ASSET MANAGEMENT, L.P.


    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    CUBIST SYSTEMATIC STRATEGIES, LLC

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 HONG KONG LIMITED

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 MIDDLE EAST FZE

    By: /s/ Rafael Lopez Espinosa
    Name: Rafael Lopez Espinosa
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person






    Get the next $AXGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXGN

    DatePrice TargetRatingAnalyst
    3/17/2025$30.00Buy
    Lake Street
    7/1/2024$13.00Outperform
    Raymond James
    11/11/2022$15.00Buy
    Jefferies
    5/9/2022$10.00 → $15.00Hold → Buy
    Canaccord Genuity
    3/11/2022$21.00Overweight
    Cantor Fitzgerald
    11/4/2021$25.00 → $20.00Market Outperform
    JMP Securities
    More analyst ratings

    $AXGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Axogen Inc.

      SC 13G/A - Axogen, Inc. (0000805928) (Subject)

      11/14/24 3:31:14 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Axogen Inc.

      SC 13G - Axogen, Inc. (0000805928) (Subject)

      11/7/24 4:34:48 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Axogen Inc.

      SC 13G/A - Axogen, Inc. (0000805928) (Subject)

      9/10/24 4:00:03 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axogen, Inc. Reports 2025 First Quarter Financial Results

      ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial Results First quarter revenue was $48.6 million, a 17.4% increase compared to the first quarter of 2024.For the first quarter of 2025, gross margin was 71.9%, down from 78.8% for the first quarter of 2024.Net loss for the quarter was $3.8 million, or $0.08 per share, compared to $6.6 million, or $0.15 per share for the first quarter of 2024.Adjusted net loss for the quart

      5/8/25 7:05:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen Announces Chief Financial Officer Transition

      ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to pursue other opportunities. Mr. Naor will remain with the Company in an advisory capacity until July 1, 2025, to ensure a smooth transition. "I want to express my sincere gratitude to Nir for his service to Axogen," said Michael Dale, President, Chief Executive O

      5/8/25 7:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

      ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visit

      4/24/25 8:04:18 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Axogen Announces Chief Financial Officer Transition

      ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to pursue other opportunities. Mr. Naor will remain with the Company in an advisory capacity until July 1, 2025, to ensure a smooth transition. "I want to express my sincere gratitude to Nir for his service to Axogen," said Michael Dale, President, Chief Executive O

      5/8/25 7:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axogen's mission to establish restoration of peripheral nerve function as an expected standard of care. Mr. Ditto brings over 15 years of leadership experience in the medical device industry, with a pr

      3/24/25 8:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulatory strategies to advance company objectives related to new product development, market approval, market development and other regulatory initiatives. Mr. Bishop will oversee all facets of Axogen's regulatory affairs, maintenance of Axogen product

      2/3/25 8:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on AxoGen with a new price target

      Lake Street initiated coverage of AxoGen with a rating of Buy and set a new price target of $30.00

      3/17/25 8:23:19 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Raymond James initiated coverage on AxoGen with a new price target

      Raymond James initiated coverage of AxoGen with a rating of Outperform and set a new price target of $13.00

      7/1/24 7:31:31 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Jefferies resumed coverage on AxoGen with a new price target

      Jefferies resumed coverage of AxoGen with a rating of Buy and set a new price target of $15.00

      11/11/22 9:07:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Financials

    Live finance-specific insights

    See more
    • Axogen, Inc. Reports 2025 First Quarter Financial Results

      ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial Results First quarter revenue was $48.6 million, a 17.4% increase compared to the first quarter of 2024.For the first quarter of 2025, gross margin was 71.9%, down from 78.8% for the first quarter of 2024.Net loss for the quarter was $3.8 million, or $0.08 per share, compared to $6.6 million, or $0.15 per share for the first quarter of 2024.Adjusted net loss for the quart

      5/8/25 7:05:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

      ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visit

      4/24/25 8:04:18 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results

      ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Financial Results and Business Highlights Fourth quarter revenue was $49.4 million, a 15.1% increase compared to the fourth quarter of 2023.Gross margin was 76.1% for the fourth quarter compared to 74.6% for the fourth quarter of 2023.Net income for the quarter was $0.4 million, or $0.01 per share, compared to net loss of $3.9 million, or $0.09 per shar

      2/25/25 7:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Axogen Inc.

      10-Q - Axogen, Inc. (0000805928) (Filer)

      5/8/25 4:38:29 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

      8-K - Axogen, Inc. (0000805928) (Filer)

      5/8/25 7:10:55 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Axogen Inc.

      DEF 14A - Axogen, Inc. (0000805928) (Filer)

      4/30/25 7:07:43 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Marketing Officer Kemp Jens

      4 - Axogen, Inc. (0000805928) (Issuer)

      3/26/25 4:53:56 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Innovation Officer Devinney Erick Wayne

      4 - Axogen, Inc. (0000805928) (Issuer)

      3/26/25 4:52:55 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Dale Michael D

      4 - Axogen, Inc. (0000805928) (Issuer)

      3/26/25 4:48:12 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care